Novo Nordisk A/S

詳細情報 Novo Nordisk A/S 企業名

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

企業情報

企業コードNVO

会社名Novo Nordisk A/S

上場日May 17, 1974

最高経営責任者「CEO」Mr. Maziar Mike Doustdar

従業員数76302

証券種類Ordinary Share

決算期末May 17

本社所在地Novo Alle 1

都市BAGSVAERD

証券取引所The Toronto Stock Exchange

国Denmark

郵便番号2880

電話番号4544448888

ウェブサイトhttps://www.novonordisk.com/

企業コードNVO

上場日May 17, 1974

最高経営責任者「CEO」Mr. Maziar Mike Doustdar

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Emil Kongshoj Larsen

Executive Vice President - International Operations

--

Mr. Jacob Martin Wiborg Rode

Head of Investor Relations

--

Ms. Thilde Hummel Bogebjerg

Executive Vice President - Quality, IT & Environmental Affairs

--

Mr. Helge Lund

Independent Chairman of the Board

--

Mr. David Moore

Executive Vice President - US Operations and Business Development

--

Mr. Karsten Munk Knudsen

Chief Financial Officer, Executive Vice President

--

Mr. Thomas Rantzau

Director, Employee Representative

--

Ms. Tania Sabroe

Executive Vice President - People, Organisation & Corporate Affairs

--

Dr. Martin Holst Lange

Executive Vice President, Chief Scientific Officer, Research & Development

--

Mr. Andreas Fibig

Independent Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Emil Kongshoj Larsen

Executive Vice President - International Operations

--

Mr. Jacob Martin Wiborg Rode

Head of Investor Relations

--

Ms. Thilde Hummel Bogebjerg

Executive Vice President - Quality, IT & Environmental Affairs

--

Mr. Helge Lund

Independent Chairman of the Board

--

Mr. David Moore

Executive Vice President - US Operations and Business Development

--

Mr. Karsten Munk Knudsen

Chief Financial Officer, Executive Vice President

--

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

事業別USD

会社名

収益

比率

Total GLP-1

5.58B

50.68%

Long-acting insulin

759.51M

6.90%

Fast-acting insulin

712.15M

6.47%

Rare blood disorders

411.75M

3.74%

Premix insulin

396.53M

3.60%

Other

3.15B

28.61%

地域別USD

会社名

収益

比率

USA

6.25B

56.75%

Canada

2.08B

18.91%

Emerging Markets

1.24B

11.26%

Region China

792.49M

7.20%

APAC

647.58M

5.88%

事業別

地域別

事業別USD

会社名

収益

比率

Total GLP-1

5.58B

50.68%

Long-acting insulin

759.51M

6.90%

Fast-acting insulin

712.15M

6.47%

Rare blood disorders

411.75M

3.74%

Premix insulin

396.53M

3.60%

Other

3.15B

28.61%

株主

更新時刻: Sat, Aug 2

株主統計

種類

株主統計

比率

Jennison Associates LLC

0.56%

Loomis, Sayles & Company, L.P.

0.37%

Fisher Investments

0.35%

Fayez Sarofim & Co.

0.33%

Folketrygdfondet

0.28%

Other

98.10%

株主統計

比率

Jennison Associates LLC

0.56%

Loomis, Sayles & Company, L.P.

0.37%

Fisher Investments

0.35%

Fayez Sarofim & Co.

0.33%

Folketrygdfondet

0.28%

Other

98.10%

種類

株主統計

比率

Investment Advisor

4.82%

Investment Advisor/Hedge Fund

2.68%

Research Firm

0.84%

Hedge Fund

0.78%

Pension Fund

0.30%

Insurance Company

0.19%

Bank and Trust

0.17%

Family Office

0.02%

Family Office

0.02%

Other

90.18%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

2754

330.35M

9.82%

-31.19M

2025Q1

2769

336.08M

9.99%

-21.71M

2024Q4

2676

348.53M

10.35%

+330.19K

2024Q3

2529

339.29M

10.15%

-6.04M

2024Q2

2456

341.24M

10.21%

+6.87M

2024Q1

2291

330.25M

9.75%

+10.89M

2023Q4

2037

314.57M

9.30%

+1.47M

2023Q3

1826

307.14M

8.91%

+4.22M

2023Q2

1692

293.83M

8.50%

+768.69K

2023Q1

1603

284.38M

8.30%

-15.92M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Jennison Associates LLC

18.82M

0.56%

-1.12M

-5.63%

Mar 31, 2025

Loomis, Sayles & Company, L.P.

12.39M

0.37%

+816.56K

+7.06%

Mar 31, 2025

Fisher Investments

11.87M

0.35%

-769.25K

-6.09%

Mar 31, 2025

Fayez Sarofim & Co.

11.21M

0.33%

-171.98K

-1.51%

Mar 31, 2025

Folketrygdfondet

9.52M

0.28%

+617.97K

+6.94%

Mar 31, 2025

Capital International Investors

9.51M

0.28%

+2.76M

+40.82%

Mar 31, 2025

Fidelity Management & Research Company LLC

8.98M

0.27%

-907.73K

-9.18%

Mar 31, 2025

Managed Account Advisors LLC

8.61M

0.26%

-774.82K

-8.25%

Mar 31, 2025

Two Sigma Investments, LP

8.00M

0.24%

+5.13M

+178.84%

Mar 31, 2025

Renaissance Technologies LLC

6.82M

0.2%

-1.49M

-17.94%

Mar 31, 2025

詳細を見る

49.900USD

Novo Nordisk A/S

49.900

概要

企業名

金融